GlaxoSmithkline Pharmaceuticals Ltd.
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states; Flutivate, a skin cream for adults, children, and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is based in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, May has averaged the highest return (+6.7%); Jan the lowest (-2.7%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.0%Negative MonthJan 2026: -2.97% | +7.2%Positive MonthFeb 2026: +7.20% | -11.2%Negative MonthMar 2026: -11.15% | +2.3%Positive MonthApr 2026: +2.29% | -5.4%Negative MonthMay 2026: -5.43% | +11.0%Positive MonthJun 2026: +10.97% | +8.3%Positive MonthJul 2026: +8.26% | +14.1%*Positive MonthAug 2026: +14.10% | β | β | β | β |
| 2025 | -12.2%Negative MonthJan 2025: -12.24% | +25.2%Positive MonthFeb 2025: +25.21% | +16.3%Positive MonthMar 2025: +16.28% | +2.9%Positive MonthApr 2025: +2.86% | +11.3%Positive MonthMay 2025: +11.34% | +2.8%Positive MonthJun 2025: +2.78% | -6.7%Negative MonthJul 2025: -6.75% | -11.9%Negative MonthAug 2025: -11.86% | -4.6%Negative MonthSep 2025: -4.56% | -1.2%Neutral MonthOct 2025: -1.22% | -2.2%Negative MonthNov 2025: -2.19% | -3.7%Negative MonthDec 2025: -3.73% |
| 2024 | +18.5%Positive MonthJan 2024: +18.47% | -3.4%Negative MonthFeb 2024: -3.37% | -10.5%Negative MonthMar 2024: -10.54% | +7.4%Positive MonthApr 2024: +7.41% | +26.0%Positive MonthMay 2024: +26.04% | +0.8%Neutral MonthJun 2024: +0.82% | +3.0%Positive MonthJul 2024: +3.03% | +0.5%Neutral MonthAug 2024: +0.46% | +0.3%Neutral MonthSep 2024: +0.34% | -1.3%Neutral MonthOct 2024: -1.27% | -10.1%Negative MonthNov 2024: -10.08% | -7.9%Negative MonthDec 2024: -7.92% |
| 2023 | -5.5%Negative MonthJan 2023: -5.47% | +7.1%Positive MonthFeb 2023: +7.06% | -0.8%Neutral MonthMar 2023: -0.79% | -6.2%Negative MonthApr 2023: -6.20% | +5.1%Positive MonthMay 2023: +5.11% | +9.1%Positive MonthJun 2023: +9.07% | -1.8%Neutral MonthJul 2023: -1.82% | +2.2%Positive MonthAug 2023: +2.15% | +8.2%Positive MonthSep 2023: +8.15% | -7.9%Negative MonthOct 2023: -7.86% | +16.4%Positive MonthNov 2023: +16.35% | +14.6%Positive MonthDec 2023: +14.58% |
| 2022 | -11.3%Negative MonthJan 2022: -11.26% | -2.7%Negative MonthFeb 2022: -2.74% | +9.4%Positive MonthMar 2022: +9.44% | -5.5%Negative MonthApr 2022: -5.54% | -3.6%Negative MonthMay 2022: -3.61% | -1.0%Neutral MonthJun 2022: -0.95% | -6.2%Negative MonthJul 2022: -6.17% | +3.7%Positive MonthAug 2022: +3.70% | -2.4%Negative MonthSep 2022: -2.40% | -3.3%Negative MonthOct 2022: -3.29% | -2.9%Negative MonthNov 2022: -2.95% | -1.3%Neutral MonthDec 2022: -1.34% |
| 2021 | β | β | β | β | β | -1.8%Neutral MonthJun 2021: -1.85% | +7.0%Positive MonthJul 2021: +7.02% | -4.8%Negative MonthAug 2021: -4.78% | -3.3%Negative MonthSep 2021: -3.27% | +1.5%Neutral MonthOct 2021: +1.48% | +13.3%Positive MonthNov 2021: +13.29% | +3.4%Positive MonthDec 2021: +3.39% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 6 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ3.72 K Cr | β | βΉ919.00 Cr | β | β | β | 9.3% | 57.1% |
| Mar 2024 | βΉ3.41 K Cr | β | βΉ585.00 Cr | β | β | β | 5.9% | -3.8% |
| Mar 2023 | βΉ3.22 K Cr | β | βΉ608.00 Cr | β | β | β | -0.1% | -64.0% |
| Mar 2022 | βΉ3.22 K Cr | β | βΉ1.69 K Cr | β | β | β | 10.2% | 372.3% |
| Mar 2021 | βΉ2.92 K Cr | β | βΉ358.00 Cr | β | β | β | -9.5% | 225.5% |
| Mar 2020 | βΉ3.23 K Cr | β | βΉ110.00 Cr | β | β | β | 3.1% | -74.1% |
| Mar 2019 | βΉ3.13 K Cr | β | βΉ425.00 Cr | β | β | β | 8.9% | 20.7% |
| Mar 2018 | βΉ2.87 K Cr | β | βΉ352.00 Cr | β | β | β | -1.1% | 4.5% |
| Mar 2017 | βΉ2.90 K Cr | β | βΉ337.00 Cr | β | β | β | 2.7% | -10.1% |
| Mar 2016 | βΉ2.83 K Cr | β | βΉ375.00 Cr | β | β | β | -14.1% | -20.6% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Dec 2013 | Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 2,546 | 3,288 | 2,826 | 2,903 | 2,872 | 3,129 | 3,225 | 2,920 | 3,218 | 3,216 | 3,407 | 3,723 | 3,767 |
| Total Expenses | 2,024 | 2,660 | 2,349 | 2,482 | 2,361 | 2,522 | 2,566 | 2,323 | 2,462 | 2,417 | 2,507 | 2,553 | 2,483 |
| EBIT / Operating Profit | 522 | 627 | 477 | 421 | 511 | 606 | 658 | 598 | 756 | 799 | 901 | 1,171 | 1,284 |
| OPM % | 20 | 19 | 17 | 14 | 18 | 19 | 20 | 20 | 23 | 25 | 26 | 31 | 34 |
| Other Income | 227 | 147 | 125 | 118 | 69 | 106 | -247 | 8 | 1,402 | 104 | -20 | 146 | 149 |
| Finance Costs | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 1 | 3 |
| Depreciation & Amortisation | 20 | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 67 | 68 |
| Profit Before Tax | 729 | 749 | 576 | 511 | 542 | 664 | 322 | 524 | 2,087 | 835 | 809 | 1,248 | 1,362 |
| Tax % | 31 | 37 | 35 | 34 | 35 | 36 | 66 | 32 | 19 | 27 | 28 | 26 | - |
| Net Profit / PAT | 502 | 472 | 375 | 337 | 352 | 425 | 110 | 358 | 1,691 | 608 | 585 | 919 | 997 |
| EPS (βΉ) | 29.63 | 27.84 | 22.11 | 19.88 | 20.78 | 25.11 | 6.50 | 21.11 | 99.79 | 35.88 | 34.51 | 54.25 | 58.85 |
| Dividend Payout % | 84 | 112 | 113 | 75 | 84 | 80 | 616 | 142 | 90 | 89 | 93 | 100 | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| GlaxoSmithkline Pharmaceuticals Ltd.this co. | βΉ40.11 K Cr | βΉ3.72 K Cr | 42.40 | 23.46 | 0.00 | 9.3% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
